Heart 1998;79:45-49 ( January )

Midodrine: a role in the management of neurocardiogenic syncope

C R Ward, J C Gray, J J Gilroy, R A Kenny

Cardiovascular Investigation Unit, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK

Correspondence to: Professor Kenny. email: r.a.kenny{at}ncl.ac.uk

Accepted for publication 28 May 1997

ObjectiveTo determine the benefit of midodrine, an  agonist, on symptom frequency and haemodynamic responses during head up tilt in patients with neurocardiogenic syncope.
SettingCardiovascular investigation unit (a secondary and tertiary referral centre for the investigation and management of syncope).
Patients16 outpatients (mean (SD) age 56 (18) years; five men) with frequent hypotensive symptoms (more than two syncopal episodes and fewer than 20 symptom free days per month), and reproducible syncope with glyceryl trinitrate (GTN) during head up tilt.
Design and interventionRandomised double blind placebo controlled study. Patients were randomised to receive either placebo or midodrine for one month. Symptom events were recorded during each study month. At the end of each study month patients completed a quality of life scoring scale (Short Form 36) and a global assessment of therapeutic response. They received GTN with head up tilt for measurement of heart rate (electrocardiography), phasic blood pressure (digital photoplethysmography), and thoracic fluid index (transthoracic impedance plethysmography) during symptom provocation.
ResultsPatients administered midodrine had an average of 7.3 more symptom free days than those who received placebo (95% confidence interval (CI) 4.6 to 9; p < 0.0001). Eleven patients reported a positive therapeutic response with midodrine (p = 0.002). All domains of quality of life showed improvement with midodrine, in particular physical function (8.1; 95% CI 3.7 to 12.2), energy and vitality (14.6; 95% CI 7.3 to 22.1), and change in health status (22.2; 95% CI 11 to 33.4 ). Fourteen patients who were given placebo had tilt induced syncope compared with six given midodrine (p = 0.01). Baseline supine systolic blood pressure was higher and heart rate lower in patients who received midodrine than in those who were given placebo ( p < 0.05). A lower thoracic fluid index in patients administered midodrine indicates increased venous return when supine and during head up tilt. There were no serious adverse effects.
ConclusionsMidodrine had a conspicuous beneficial effect on symptom frequency, symptoms during head up tilt, and quality of life. Midodrine is recommended for the treatment of neurocardiogenic syncope in patients with frequent symptoms.

Keywords: midodrine;  neurocardiogenic syncope;  head up tilt test

---

© 1998 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Developed in collaboration with, , European Heart Rhythm Association (EHRA), , Heart Failure Association (HFA), , and Heart Rhythm Society (HRS), , Endorsed by the following societies, , European Society of Emergency Medicine (EuSEM), , European Federation of Internal Medicine (EFIM), , European Union Geriatric Medicine Society (EUGMS), , American Geriatrics Society (AGS), , European Neurological Society (ENS), , European Federation of Autonomic Societies (EFAS), , American Autonomic Society (AAS), , Authors/Task Force Members, , Moya, A., Sutton, R., Ammirati, F., Blanc, J.-J., Brignole, M., Dahm, J. B., Deharo, J.-C., Gajek, J., Gjesdal, K., Krahn, A., Massin, M., Pepi, M., Pezawas, T., Granell, R. R., Sarasin, F., Ungar, A., van Dijk, J. G., Walma, E. P., Wieling, W., External Contributors, , Abe, H., Benditt, D. G., Decker, W. W., Grubb, B. P., Kaufmann, H., Morillo, C., Olshansky, B., Parry, S. W., Sheldon, R., Shen, W. K., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., McGregor, K., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Vardas, P., Widimsky, P., Document Reviewers, , Auricchio, A., Acarturk, E., Andreotti, F., Asteggiano, R., Bauersfeld, U., Bellou, A., Benetos, A., Brandt, J., Chung, M. K., Cortelli, P., Da Costa, A., Extramiana, F., Ferro, J., Gorenek, B., Hedman, A., Hirsch, R., Kaliska, G., Kenny, R. A., Kjeldsen, K. P., Lampert, R., Molgard, H., Paju, R., Puodziukynas, A., Raviele, A., Roman, P., Scherer, M., Schondorf, R., Sicari, R., Vanbrabant, P., Wolpert, C., Zamorano, J. L. (2009). Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 30: 2631-2671 [Full Text]  
• Benditt, D. G., Nguyen, J. T. (2009). Syncope: therapeutic approaches.. J Am Coll Cardiol 53: 1741-1751 [Abstract] [Full Text]  
• Brignole, M., Blanc, J.-J., Sutton, R., Moya, A. (2009). CHAPTER 26 Syncope. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Tan, M. P., Parry, S. W. (2008). Vasovagal syncope in the older patient.. J Am Coll Cardiol 51: 599-606 [Abstract] [Full Text]  
• Fink, G., Li, M., Lau, Y., Osborn, J., Watts, S. (2007). Chronic Activation of Endothelin B Receptors: New Model of Experimental Hypertension. Hypertension 50: 512-518 [Abstract] [Full Text]  
• Fitzpatrick, A. P, Cooper, P. (2006). Diagnosis and management of patients with blackouts.. Heart 92: 559-568 [Full Text]  
• Sheldon, R., Connolly, S., Rose, S., Klingenheben, T., Krahn, A., Morillo, C., Talajic, M., Ku, T., Fouad-Tarazi, F., Ritchie, D., Koshman, M.-L., for the POST Investigators, (2006). Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope. Circulation 113: 1164-1170 [Abstract] [Full Text]  
• Grubb, B. P. (2005). Neurocardiogenic Syncope. NEJM 352: 1004-1010 [Full Text]  
• Chen-Scarabelli, C., Scarabelli, T. M (2004). Neurocardiogenic syncope. BMJ 329: 336-341 [Full Text]  
• (2004). Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology. Europace 6: 467-537 [Full Text]  
• Kapoor, W. N. (2003). Is There an Effective Treatment for Neurally Mediated Syncope?. JAMA 289: 2272-2275 [Full Text]  
• McLeod, K A (2003). Syncope in childhood. Arch. Dis. Child. 88: 350-353 [Abstract] [Full Text]  
• Shaw, F. E, Bond, J., Richardson, D. A, Dawson, P., Steen, I N., McKeith, I. G, Kenny, R. A. (2003). Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: randomised controlled trial. BMJ 326: 73-73 [Abstract] [Full Text]  
• Schroeder, C., Bush, V. E., Norcliffe, L. J., Luft, F. C., Tank, J., Jordan, J., Hainsworth, R. (2002). Water Drinking Acutely Improves Orthostatic Tolerance in Healthy Subjects. Circulation 106: 2806-2811 [Abstract] [Full Text]  
• Kapoor, W. N. (2002). Current Evaluation and Management of Syncope. Circulation 106: 1606-1609 [Full Text]  
• Flevari, P., Livanis, E. G., Theodorakis, G. N., Zarvalis, E., Mesiskli, T., Kremastinos, D. T. h (2002). Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. J Am Coll Cardiol 40: 499-504 [Abstract] [Full Text]  
• Kouakam, C., Vaksmann, G., Pachy, E., Lacroix, D., Rey, C., Kacet, S. (2001). Long-term follow-up of children and adolescents with syncope; predictor of syncope recurrence. Eur Heart J 22: 1618-1625 [Abstract]  
• McLeod, K. A (2001). CONGENITAL HEART DISEASE: Dizziness and syncope in adolescence. Heart 86: 350-354 [Full Text]  
• Task Force on Syncope, European Society of Cardiol, , Brignole, M, Alboni, P, Benditt, D, Bergfeldt, L, Blanc, J.J, Bloch Thomsen, P.E, van Dijk, J.G, Fitzpatrick, A, Hohnloser, S, Janousek, J, Kapoor, W, Kenny, R.A, Kulakowski, P, Moya, A, Raviele, A, Sutton, R, Theodorakis, G, Wieling, W (2001). Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 22: 1256-1306 [Abstract]  
• Ammirati, F., Colivicchi, F., Santini, M. (2001). Permanent Cardiac Pacing Versus Medical Treatment for the Prevention of Recurrent Vasovagal Syncope : A Multicenter, Randomized, Controlled Trial. Circulation 104: 52-57 [Abstract] [Full Text]  
• Ramsdell, C. D., Mullen, T. J., Sundby, G. H., Rostoft, S., Sheynberg, N., Aljuri, N., Maa, M., Mukkamala, R., Sherman, D., Toska, K., Yelle, J., Bloomfield, D., Williams, G. H., Cohen, R. J. (2001). Midodrine prevents orthostatic intolerance associated with simulated spaceflight. J. Appl. Physiol. 90: 2245-2248 [Abstract] [Full Text]  
• Madrid, A. H., Ortega, J., Rebollo, J. G., Manzano, J. G., Segovia, J. G., Sanchez, A., Pena, G., Moro, C. (2001). Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol 37: 554-559 [Abstract] [Full Text]  
• Rowe, P. C., Calkins, H., DeBusk, K., McKenzie, R., Anand, R., Sharma, G., Cuccherini, B. A., Soto, N., Hohman, P., Snader, S., Lucas, K. E., Wolff, M., Straus, S. E. (2001). Fludrocortisone Acetate to Treat Neurally Mediated Hypotension in Chronic Fatigue Syndrome: A Randomized Controlled Trial. JAMA 285: 52-59 [Abstract] [Full Text]  
• Sheldon, R., Rose, S. (2001). Components of clinical trials for vasovagal syncope. Europace 3: 233-240 [Abstract]  
• Raviele, A., Giada, F., Sutton, R., Alboni, P., Brignole, M., Del Rosso, A., di Girolamo, E., Luise, R., Menozzi, C. (2001). The Vasovagal Syncope and Pacing (Synpace) trial: rationale and study design. Europace 3: 336-341 [Abstract]  
• Fenton, A. M., Hammill, S. C., Rea, R. F., Low, P. A., Shen, W.-K. (2000). Vasovagal Syncope. ANN INTERN MED 133: 714-725 [Abstract] [Full Text]  
• Brignole, M., Menozzi, C., Del Rosso, A., Costa, S., Gaggioli, G., Bottoni, N., Bartoli, P., Sutton, R. (2000). New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification: Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge. Europace 2: 66-76 [Abstract]  
• Parry, S.W., Kenny, R.A. (1999). The management of vasovagal syncope. QJM 92: 697-705 [Full Text]  
• KURBAAN, A S, SUTTON, R (1999). Pacing for vasovagal syncope. Heart 82: 649-650 [Full Text]  
• Raviele, A., Brignole, M., Sutton, R., Alboni, P., Giani, P., Menozzi, C., Moya, A. (1999). Effect of Etilefrine in Preventing Syncopal Recurrence in Patients With Vasovagal Syncope : A Double-Blind, Randomized, Placebo-Controlled Trial. Circulation 99: 1452-1457 [Abstract] [Full Text]